ECSP10010035A - Amidas heterocíclicas y sus métodos de uso - Google Patents

Amidas heterocíclicas y sus métodos de uso

Info

Publication number
ECSP10010035A
ECSP10010035A EC2010010035A ECSP10010035A ECSP10010035A EC SP10010035 A ECSP10010035 A EC SP10010035A EC 2010010035 A EC2010010035 A EC 2010010035A EC SP10010035 A ECSP10010035 A EC SP10010035A EC SP10010035 A ECSP10010035 A EC SP10010035A
Authority
EC
Ecuador
Prior art keywords
compounds
methods
heterocyclic
amidas
hedgehog pathway
Prior art date
Application number
EC2010010035A
Other languages
English (en)
Inventor
Alexander Hird
James Walter Janetka
Leslie Dakin
Xiaolan Zheng
Qibin Su
Bin Yang
Benjamin Fauber
Daniel John Russell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39967396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010035(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP10010035A publication Critical patent/ECSP10010035A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se relaciona con compuestos amidas heterocíclicas que son útiles para inhibir la ruta Hedgehog y con su uso para tratar una enfermedad o una afección mediada, solo o en parte, por la inhibición de la ruta Hedgehog. También se revelan métodos para fabricar estos compuestos, las composiciones farmacéuticas que incluyen estos compuestos y el uso de tales compuestos en la fabricación de medicamentos para tratar tales enfermedades o afecciones en un individuo. Fórmula (IA) con la condición de que R2 o R3 es (Z).
EC2010010035A 2007-08-31 2010-03-12 Amidas heterocíclicas y sus métodos de uso ECSP10010035A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96936407P 2007-08-31 2007-08-31
US3665808P 2008-03-14 2008-03-14

Publications (1)

Publication Number Publication Date
ECSP10010035A true ECSP10010035A (es) 2010-04-30

Family

ID=39967396

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010035A ECSP10010035A (es) 2007-08-31 2010-03-12 Amidas heterocíclicas y sus métodos de uso

Country Status (23)

Country Link
US (1) US20100311748A1 (es)
EP (1) EP2188255A1 (es)
JP (1) JP2010537967A (es)
KR (1) KR20100047901A (es)
CN (1) CN101835752A (es)
AR (1) AR068140A1 (es)
AU (1) AU2008291921A1 (es)
BR (1) BRPI0816050A2 (es)
CA (1) CA2696767A1 (es)
CL (1) CL2008002560A1 (es)
CO (1) CO6321229A2 (es)
CR (1) CR11299A (es)
DO (1) DOP2010000067A (es)
EA (1) EA201000365A1 (es)
EC (1) ECSP10010035A (es)
MX (1) MX2010002353A (es)
NI (1) NI201000033A (es)
PE (1) PE20090641A1 (es)
SV (1) SV2010003497A (es)
TW (1) TW200918521A (es)
UY (1) UY31314A1 (es)
WO (1) WO2009027746A1 (es)
ZA (1) ZA201001194B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124651A1 (en) 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
AU2008335709A1 (en) * 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
JP5670325B2 (ja) * 2008-06-19 2015-02-18 エックスカバリー ホールディング カンパニー エルエルシー キナーゼ阻害化合物としての置換されたピリダジンカルボキサミド化合物
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
CA2785204C (en) 2010-01-07 2016-01-05 Selexagen Therapeutics, Inc. Hedgehog inhibitors
WO2011085261A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2013061297A1 (en) * 2011-10-28 2013-05-02 Pfizer Limited Pyridazine Derivatives Useful in Therapy
WO2013102142A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
DK2970139T3 (en) 2013-03-15 2018-08-13 Biomarin Pharm Inc HDAC inhibitors
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EP3919056B1 (en) 2013-03-15 2024-08-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
ES2860648T5 (es) 2014-02-07 2024-11-27 Global Blood Therapeutics Inc Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
CN104529905B (zh) * 2014-12-09 2017-10-31 沈阳药科大学 N‑3‑苯并咪唑酰双胺类衍生物及其制备方法与应用
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
PL3302428T3 (pl) 2015-06-04 2026-04-13 Sol-Gel Technologies Ltd. Preparaty do zastosowania miejscowego do dostarczania związków inhibitora hedgehog i ich zastosowanie
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
AR113206A1 (es) 2017-01-10 2020-02-19 Bayer Cropscience Ag Derivados heterocíclicos como pesticidas
UY37556A (es) 2017-01-10 2018-07-31 Bayer Ag Derivados heterocíclicos como pesticidas
JP2020512976A (ja) * 2017-03-27 2020-04-30 ファーマケア，インク． アポトーシスシグナル調節キナーゼ１（ａｓｋ１）阻害剤化合物
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
CN110759831B (zh) * 2019-10-16 2022-09-27 浙江金伯士药业有限公司 制备常山酮中间体2-氨基-4-溴-5-氯苯甲酸方法
AR121544A1 (es) 2020-03-12 2022-06-15 3 2 Pharma Inhibidores de la vía de señalización por cbp / catenina y sus usos
EP4337202A4 (en) 2021-06-18 2025-04-02 Aligos Therapeutics, Inc. METHODS AND COMPOSITIONS FOR TARGETING PD-L1
EP4448512A4 (en) 2021-12-16 2025-11-19 Aligos Therapeutics Inc METHODS AND COMPOSITIONS FOR TARGETING PD-L1
WO2026082744A1 (en) * 2024-10-15 2026-04-23 Medetia Treatment of genetic neurodevelopmental, neurosensory and/or weight control disorders
CN119462558B (zh) * 2024-10-18 2025-09-19 河南中医药大学 一种布美他尼衍生物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7319111B2 (en) * 2003-02-20 2008-01-15 Encysive Pharmaceuticals, Inc. Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists
ES2377430T3 (es) * 2004-09-02 2012-03-27 Genentech, Inc. Inhibidores piridílicos de la señalización de hedgehog
CA2628074C (en) * 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Aminodihydrothiazine derivative

Also Published As

Publication number Publication date
EA201000365A1 (ru) 2010-10-29
BRPI0816050A2 (pt) 2017-05-02
AR068140A1 (es) 2009-11-04
CN101835752A (zh) 2010-09-15
PE20090641A1 (es) 2009-06-26
UY31314A1 (es) 2009-03-31
CA2696767A1 (en) 2009-03-05
MX2010002353A (es) 2010-05-03
US20100311748A1 (en) 2010-12-09
AU2008291921A1 (en) 2009-03-05
KR20100047901A (ko) 2010-05-10
DOP2010000067A (es) 2010-05-31
CR11299A (es) 2010-05-28
CL2008002560A1 (es) 2009-07-17
WO2009027746A1 (en) 2009-03-05
TW200918521A (en) 2009-05-01
ZA201001194B (en) 2011-12-28
EP2188255A1 (en) 2010-05-26
JP2010537967A (ja) 2010-12-09
NI201000033A (es) 2010-12-07
SV2010003497A (es) 2010-07-06
CO6321229A2 (es) 2011-09-20

Similar Documents

Publication Publication Date Title
ECSP10010035A (es) Amidas heterocíclicas y sus métodos de uso
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
DOP2011000279A (es) Derivados de benzofuranilo usados como inhibidores de glucoquinasa
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
GT200600193A (es) Imidazoquinolines como inhibidores de lipidos kinase
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ECSP088620A (es) 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
PA8842101A1 (es) Heteroarilos sustituidos
UY30843A1 (es) Derivados de isoquinolona sustituidos con ciloalquilamina
UA96785C2 (uk) Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
CR10479A (es) Modulares bencimidazolicos de vr1
CR20110255A (es) Nuevos compuestos 578
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
BR112012013918A2 (pt) inibidores de diacil glicerol acil transferase
NO20090234L (no) Tricyklisk sammensetning og farmasoytisk anvendelse derav
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos